MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Kodu・Aktsiate loetelu・Schrodinger Inc

Schrodinger Inc

Suletud

SektorTervishoid

11.58 0.52

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.47

Max

11.58

Põhinäitajad
By Trading Economics
Sissetulek	169M 136M
Müük	33M 87M
Aktsiakasum	-0.18
Kasumimarginaal	155.644
Töötajad	850
EBITDA	67M 36M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+67.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-9.3M 817M
Eelmine avamishind	11.06
Eelmine sulgemishind	11.58

Uudiste sentiment

By Acuity

100%

336 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

23.27 / 26.13 Toetus ja vastupanu

Schrodinger Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. apr 2026, 04:27 UTC

Uudisväärsed sündmused

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 18:30 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. apr 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. apr 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. apr 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. apr 2026, 16:50 UTC

Uudisväärsed sündmused

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. apr 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 16:12 UTC

Tulu

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Equities Roundup: Market Talk

3. apr 2026, 15:56 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

3. apr 2026, 15:20 UTC

Uudisväärsed sündmused

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. apr 2026, 15:08 UTC

Omandamised, ülevõtmised, äriostud

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. apr 2026, 14:11 UTC

Market Talk

Uudisväärsed sündmused

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. apr 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. apr 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. apr 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. apr 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. apr 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. apr 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. apr 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. apr 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. apr 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. apr 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. apr 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Schrodinger Inc Prognoos

Hinnasiht

By TipRanks

67.97% tõus

12 kuu keskmine prognoos

Keskmine 19.4 USD 67.97%

Kõrge 25 USD

Madal 13 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Schrodinger Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Schrodinger Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

23.27 / 26.13Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

336 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.